Dianthus Therapeutics, Inc.DNTHNASDAQ

Revenue (LTM)

$2M

-67.3% YoY

Net Income (LTM)

$-162M

-91.1% YoY

Free Cash Flow

$-129M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	1	6↑334.8%	3↓56.0%	6↑120.6%	2↓67.3%
Gross Profit	1	6↑334.8%	3↓56.0%	6↑120.6%	2↓67.3%
Operating Income	-13	-30↓127.0%	-48↓62.2%	-102↓111.5%	-178↓74.7%
Net Income	-13	-28↓117.2%	-44↓53.0%	-85↓95.1%	-162↓91.1%
EBITDA	-13	-30↓125.9%	-48↓61.8%	-101↓112.2%	-178↓75.4%
EPS Diluted	-3.82	-7.60↓99.0%	-8.45↓11.2%	-2.55↑69.8%	-4.20↓64.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	132	15↓88.3%	132↑761.2%	23↓82.8%	51↑124.1%
Total Current Assets	181	82↓54.6%	177↑116.3%	281↑58.3%	409↑45.8%
Total Assets	190	83↓56.2%	179↑115.9%	374↑108.5%	531↑42.0%
Total Current Liabilities	11	8↓24.3%	10↑17.1%	18↑91.6%	31↑66.6%
Total Liabilities	17	9↓45.2%	11↑11.4%	22↑104.4%	38↑74.3%
Total Equity	173	74↓57.3%	169↑129.3%	352↑108.7%	493↑40.0%
Total Debt	0	1	1↓25.8%	1↑154.9%	1↓7.0%
Net Debt	-132	-15↑88.9%	-132↓803.8%	-21↑83.8%	-50↓133.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-60	-29↑51.2%	-37↓26.8%	-78↓112.1%	-129↓65.1%
Capital Expenditure	-1	-0↑89.0%	-0↑20.9%	-0↑4.5%	-0↓102.9%
Free Cash Flow	-61	-29↑52.0%	-37↓26.6%	-78↓111.7%	-129↓65.1%
Stock-Based Comp	0	2	3↑91.0%	13↑344.6%	23↑76.8%
Net Change in Cash	73	8↓89.4%	117↑1402.1%	-109↓193.5%	28↑125.8%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance